Updates on the latest news and insights from Esperante and its portfolio.
April 28, 2022
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization, which approves Kapruvia® for use in all member states of the European Union plus Iceland, Liechtenstein and Norway, follows the U.S. Food and Drug Administration (FDA) approval of KORSUVATM (difelikefalin) injection inAugust 2021 for the same indication. Kapruvia® will be the first therapy available in Europe for the treatment of CKD-associated pruritus in hemodialysis patients.